The available information doesn't include specific results for Intellia Therapeutics' NTLA-2001 CRISPR gene editing trial for ATTR-CM. For the most current trial data, checking ClinicalTrials.gov or Intellia's official updates directly would be the best move.
What is known is that the broader landscape of ATTR-CM treatment Show Full Answer
The available information doesn't include specific results for Intellia Therapeutics' NTLA-2001 CRISPR gene editing trial for ATTR-CM. For the most current trial data, checking ClinicalTrials.gov or Intellia's official updates directly would be the best move.
What is known is that the broader landscape of ATTR-CM treatment is advancing rapidly. A drug called ALXN2220 has received FDA fast-track status and is showing early promise in actually clearing amyloid deposits from the heart — something current treatments don't do. Currently FDA-approved treatments for ATTR-CM include:
- Tafamidis (Vyndamax) – stabilizes the TTR protein
- Acoramidis (Attruby) – also a TTR stabilizer
- Vutrisiran (Amvuttra) – a gene-silencing injection given every 3 months
These treatments slow disease progression significantly, improving survival, quality of life, and reducing hospitalizations — though they don't reverse existing damage.
Speaking with a specialist about the latest trial options, including CRISPR-based therapies, is always worth exploring.
July 7
Continue with Facebook
Continue with Email
Join
Your Privacy Choices
